Jiangsu Hillgene Biopharma

Executive Summary

Jiangsu Hillgene Biopharma is a China-based Contract Development and Manufacturing Organization (CDMO) specializing in cell and gene therapies, including CAR-T, CAR-NK, and TCR-T. Founded in 2017 and headquartered in Suzhou, the company provides end-to-end CDMO solutions from lentiviral vector production to GMP manufacturing, complemented by its proprietary BlueKit quality control testing kits. With 200-500 employees, Hillgene serves both domestic and international clients, accelerating the development and commercialization of advanced therapies. The company's integrated platform and focus on quality testing differentiate it in the competitive CDMO landscape. The cell and gene therapy CDMO market is poised for rapid growth, driven by increasing approvals and pipeline expansion in China and globally. Hillgene is well-positioned to capture this demand through its established capabilities, strategic location in Suzhou's biotech hub, and ongoing capacity expansion. While the company faces competition from larger global players and regulatory uncertainties, its proprietary testing kits and early mover advantage in lentiviral vector manufacturing provide a competitive edge. We view Hillgene as a solid platform play in the cell therapy ecosystem, with potential for strategic partnerships and client wins.

Upcoming Catalysts (preview)

• Q3 2026Strategic partnership or manufacturing deal with a major biotech60% success
• H2 2026Announcement of new GMP manufacturing facility or capacity expansion70% success
• 2027Regulatory approval of a client therapy using Hillgene's CDMO services40% success